Cargando…

Improvement in Plasma Drug Activity during the Early Treatment Interval among Tanzanian Patients with Multidrug-Resistant Tuberculosis

BACKGROUND: Individual pharmacokinetic variability may be common in patients treated for multidrug-resistant tuberculosis (MDR-TB) but data are sparse from resource-limited settings and across the early treatment interval. METHODS: Plasma drug activity, as measured by the TB Drug Activity (TDA) assa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ndusilo, Norah D., Heysell, Scott K., Mpagama, Stellah G., Gratz, Jean, Segesela, Farida H., Pazia, Saumu J., Wang, Xin-Qun, Houpt, Eric R., Kibiki, Gibson S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376785/
https://www.ncbi.nlm.nih.gov/pubmed/25816161
http://dx.doi.org/10.1371/journal.pone.0122769
_version_ 1782363786277027840
author Ndusilo, Norah D.
Heysell, Scott K.
Mpagama, Stellah G.
Gratz, Jean
Segesela, Farida H.
Pazia, Saumu J.
Wang, Xin-Qun
Houpt, Eric R.
Kibiki, Gibson S.
author_facet Ndusilo, Norah D.
Heysell, Scott K.
Mpagama, Stellah G.
Gratz, Jean
Segesela, Farida H.
Pazia, Saumu J.
Wang, Xin-Qun
Houpt, Eric R.
Kibiki, Gibson S.
author_sort Ndusilo, Norah D.
collection PubMed
description BACKGROUND: Individual pharmacokinetic variability may be common in patients treated for multidrug-resistant tuberculosis (MDR-TB) but data are sparse from resource-limited settings and across the early treatment interval. METHODS: Plasma drug activity, as measured by the TB Drug Activity (TDA) assay at 2 and 4 weeks of treatment with a standardized MDR-TB regimen was performed in patients with pulmonary MDR-TB from Tanzania. TDA values were correlated with measures of early treatment outcome including every two week collection of sputum for time-to-positivity (TTP) in liquid culture from the MGIT 960 automated system. Patients were evaluated at 24 weeks and those surviving without delayed sputum culture conversion (>8 weeks), culture reversion after previously negative, or weight loss were defined as having a favorable outcome. RESULTS: Twenty-five patients were enrolled with a mean age of 37 ±12 years. All were culture positive from the pretreatment sputum sample with a mean TTP in MGIT of 257 ±134 hours, and the median time to culture conversion on treatment was 6 weeks. Twenty patients (80%) had an increase in TDA, with the overall mean TDA at 2 weeks of 2.1 ±0.7 compared to 2.4 ±0.8 at 4 weeks (p = 0.005). At 2 weeks 13 subjects (52%) had a TDA value > 2-log killing against their own M. tuberculosis isolate compared to 17 subjects (68%) at 4 weeks (McNemar’s exact test p = 0.29). An interim treatment outcome was able to be determined in 23 patients (92%), of whom 7 had a poor outcome (30%). An increase in TDA from week 2 to week 4 was associated with favorable outcome, [unadjusted OR = 20.0, 95% CI: 1.61–247.98, exact p = 0.017 and adjusted OR = 19.33, 95% CI: 1.55–241.5, exact p = 0.023]. CONCLUSIONS: The majority of patients with MDR-TB in Tanzania had an increase in plasma drug activity from week 2 to week 4 of treatment as measured by the TDA assay. Understanding the etiology and full impact of this dynamic may inform therapeutic intervention.
format Online
Article
Text
id pubmed-4376785
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-43767852015-04-04 Improvement in Plasma Drug Activity during the Early Treatment Interval among Tanzanian Patients with Multidrug-Resistant Tuberculosis Ndusilo, Norah D. Heysell, Scott K. Mpagama, Stellah G. Gratz, Jean Segesela, Farida H. Pazia, Saumu J. Wang, Xin-Qun Houpt, Eric R. Kibiki, Gibson S. PLoS One Research Article BACKGROUND: Individual pharmacokinetic variability may be common in patients treated for multidrug-resistant tuberculosis (MDR-TB) but data are sparse from resource-limited settings and across the early treatment interval. METHODS: Plasma drug activity, as measured by the TB Drug Activity (TDA) assay at 2 and 4 weeks of treatment with a standardized MDR-TB regimen was performed in patients with pulmonary MDR-TB from Tanzania. TDA values were correlated with measures of early treatment outcome including every two week collection of sputum for time-to-positivity (TTP) in liquid culture from the MGIT 960 automated system. Patients were evaluated at 24 weeks and those surviving without delayed sputum culture conversion (>8 weeks), culture reversion after previously negative, or weight loss were defined as having a favorable outcome. RESULTS: Twenty-five patients were enrolled with a mean age of 37 ±12 years. All were culture positive from the pretreatment sputum sample with a mean TTP in MGIT of 257 ±134 hours, and the median time to culture conversion on treatment was 6 weeks. Twenty patients (80%) had an increase in TDA, with the overall mean TDA at 2 weeks of 2.1 ±0.7 compared to 2.4 ±0.8 at 4 weeks (p = 0.005). At 2 weeks 13 subjects (52%) had a TDA value > 2-log killing against their own M. tuberculosis isolate compared to 17 subjects (68%) at 4 weeks (McNemar’s exact test p = 0.29). An interim treatment outcome was able to be determined in 23 patients (92%), of whom 7 had a poor outcome (30%). An increase in TDA from week 2 to week 4 was associated with favorable outcome, [unadjusted OR = 20.0, 95% CI: 1.61–247.98, exact p = 0.017 and adjusted OR = 19.33, 95% CI: 1.55–241.5, exact p = 0.023]. CONCLUSIONS: The majority of patients with MDR-TB in Tanzania had an increase in plasma drug activity from week 2 to week 4 of treatment as measured by the TDA assay. Understanding the etiology and full impact of this dynamic may inform therapeutic intervention. Public Library of Science 2015-03-27 /pmc/articles/PMC4376785/ /pubmed/25816161 http://dx.doi.org/10.1371/journal.pone.0122769 Text en © 2015 Ndusilo et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Ndusilo, Norah D.
Heysell, Scott K.
Mpagama, Stellah G.
Gratz, Jean
Segesela, Farida H.
Pazia, Saumu J.
Wang, Xin-Qun
Houpt, Eric R.
Kibiki, Gibson S.
Improvement in Plasma Drug Activity during the Early Treatment Interval among Tanzanian Patients with Multidrug-Resistant Tuberculosis
title Improvement in Plasma Drug Activity during the Early Treatment Interval among Tanzanian Patients with Multidrug-Resistant Tuberculosis
title_full Improvement in Plasma Drug Activity during the Early Treatment Interval among Tanzanian Patients with Multidrug-Resistant Tuberculosis
title_fullStr Improvement in Plasma Drug Activity during the Early Treatment Interval among Tanzanian Patients with Multidrug-Resistant Tuberculosis
title_full_unstemmed Improvement in Plasma Drug Activity during the Early Treatment Interval among Tanzanian Patients with Multidrug-Resistant Tuberculosis
title_short Improvement in Plasma Drug Activity during the Early Treatment Interval among Tanzanian Patients with Multidrug-Resistant Tuberculosis
title_sort improvement in plasma drug activity during the early treatment interval among tanzanian patients with multidrug-resistant tuberculosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376785/
https://www.ncbi.nlm.nih.gov/pubmed/25816161
http://dx.doi.org/10.1371/journal.pone.0122769
work_keys_str_mv AT ndusilonorahd improvementinplasmadrugactivityduringtheearlytreatmentintervalamongtanzanianpatientswithmultidrugresistanttuberculosis
AT heysellscottk improvementinplasmadrugactivityduringtheearlytreatmentintervalamongtanzanianpatientswithmultidrugresistanttuberculosis
AT mpagamastellahg improvementinplasmadrugactivityduringtheearlytreatmentintervalamongtanzanianpatientswithmultidrugresistanttuberculosis
AT gratzjean improvementinplasmadrugactivityduringtheearlytreatmentintervalamongtanzanianpatientswithmultidrugresistanttuberculosis
AT segeselafaridah improvementinplasmadrugactivityduringtheearlytreatmentintervalamongtanzanianpatientswithmultidrugresistanttuberculosis
AT paziasaumuj improvementinplasmadrugactivityduringtheearlytreatmentintervalamongtanzanianpatientswithmultidrugresistanttuberculosis
AT wangxinqun improvementinplasmadrugactivityduringtheearlytreatmentintervalamongtanzanianpatientswithmultidrugresistanttuberculosis
AT houptericr improvementinplasmadrugactivityduringtheearlytreatmentintervalamongtanzanianpatientswithmultidrugresistanttuberculosis
AT kibikigibsons improvementinplasmadrugactivityduringtheearlytreatmentintervalamongtanzanianpatientswithmultidrugresistanttuberculosis